title: New phosphodiesterase inhibitors in the treatment of erectile dysfunction.
abstract: Sildenafil revolutionised the treatment of erectile dysfunction (ED) on its introduction in 1998. Not only is it effective, but is, perhaps even more importantly, an extremely acceptable manner in which to treat ED (i.e., oral pharmacotherapy), compared to the other treatments that were available at that time (e.g., intracavernosal injection). Whilst sildenafil remains the market leader for ED treatment, it does have some shortcomings: its clinical efficacy is diminished in 'difficult to treat' patient groups, such as diabetics, side effects, such as blue-tinged vision and headache, and the need to time the ingestion of sildenafil to 1 h prior to expected time of sexual intercourse. Recently, newer phosphodiesterase inhibitors ('sons of viagra') have become available, and potentially to improve upon, what has become regarded as the gold standard for ED treatment. This review article discusses the differences between vardenafil, tadalafil and sildenafil, in order to allow the clinician to make an informed decision as to which phosphodiesterase inhibitor to prescribe when dealing with the ever expanding number of patients seeking help for ED.
authors.affiliation: Good Hope Hospital, Sutton Coldfield, West Midlands.
authors.forename: Paul C B
authors.initials: PC
authors.lastname: Anderson
authors.forename: Lyndon
authors.initials: L
authors.lastname: Gommersall
authors.forename: Dickon
authors.initials: D
authors.lastname: Hayne
authors.forename: Manit
authors.initials: M
authors.lastname: Arya
authors.forename: Hitendra R H
authors.initials: HR
authors.lastname: Patel
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D002243:Carbolines / Q000627:therapeutic use; D048909:Diabetes Complications / Q000188:drug therapy; D004347:Drug Interactions; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D018783:Impotence, Vasculogenic / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D000068581:Tadalafil; D014227:Triazines; D000069058:Vardenafil Dihydrochloride
chemical_list: D002243:Carbolines; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases